Cladribine in hairy cell leukemia

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Hairy cell leukemia (HCL) treatment with cladribine leads to prolonged remissions and improved survival.
• Complete remission (CR) in HCL patients treated with cladribine does not guarantee a cure, as minimal residual disease (MRD) is often detected.
• Current response criteria for HCL do not include sensitive molecular techniques for MRD detection.

Purpose of the Study:

• To evaluate the curative potential of cladribine in HCL.
• To assess the utility of sensitive molecular techniques for MRD detection post-treatment.
• To explore combination therapies for eradicating MRD in HCL.

Main Methods:

• Utilized polymerase chain reaction (PCR) with clonoegenic probes targeting immunoglobulin heavy-chain gene hypervariable regions to detect MRD in bone marrow biopsy specimens.
• Assessed treatment outcomes, including CR, partial remission (PR), and treatment failure, in patients receiving cladribine alone and in combination with rituximab.
• Monitored MRD status using PCR before and after treatment interventions.

Main Results:

• All seven patients in morphologic CR after cladribine were PCR positive for MRD, indicating cladribine is not curative.
• In a separate cohort, all 10 patients treated with cladribine and rituximab were initially PCR positive for MRD.
• Following rituximab therapy, all 10 patients achieved a complete hematologic response, with long-term MRD eradication requiring further study.

Conclusions:

• Cladribine is a significant therapeutic advance for HCL, improving patient prognosis.
• Sensitive molecular methods reveal that cladribine alone does not eradicate MRD, questioning its curative effect.
• Combination therapy, such as cladribine with rituximab, holds promise for MRD eradication and potentially curative treatment strategies in HCL.